Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells $101,599.68 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 3,489 shares of the business’s stock in a transaction on Wednesday, January 14th. The shares were sold at an average price of $29.12, for a total transaction of $101,599.68. Following the sale, the director directly owned 737,770 shares of the company’s stock, valued at approximately $21,483,862.40. The trade was a 0.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Cyrus Harmon also recently made the following trade(s):

• On Tuesday, January 20th, Cyrus Harmon sold 10,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $26.88, for a total value of $268,800.00.
• On Monday, December 22nd, Cyrus Harmon sold 2,881 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.53, for a total value of $82,194.93.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $26.42 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. The stock has a 50-day simple moving average of $26.55 and a two-hundred day simple moving average of $13.89. The firm has a market capitalization of $1.81 billion, a PE ratio of -14.13 and a beta of 1.92. Olema Pharmaceuticals, Inc. has a 52-week low of $2.86 and a 52-week high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Institutional Trading of Olema Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Paradigm Biocapital Advisors LP grew its stake in shares of Olema Pharmaceuticals by 0.4% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 6,794,172 shares of the company’s stock worth $66,515,000 after buying an additional 30,000 shares in the last quarter. Deep Track Capital LP boosted its holdings in Olema Pharmaceuticals by 0.8% during the 3rd quarter. Deep Track Capital LP now owns 3,470,172 shares of the company’s stock valued at $33,973,000 after acquiring an additional 27,339 shares during the period. Geode Capital Management LLC boosted its holdings in Olema Pharmaceuticals by 22.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock valued at $5,650,000 after acquiring an additional 242,997 shares during the period. Candriam S.C.A. grew its position in Olema Pharmaceuticals by 46.9% in the 3rd quarter. Candriam S.C.A. now owns 1,249,727 shares of the company’s stock valued at $12,235,000 after acquiring an additional 399,273 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Olema Pharmaceuticals by 193.4% in the second quarter. Ameriprise Financial Inc. now owns 1,172,863 shares of the company’s stock worth $4,996,000 after purchasing an additional 773,064 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

OLMA has been the subject of a number of recent analyst reports. Piper Sandler started coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 price target for the company. Oppenheimer upped their target price on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. JPMorgan Chase & Co. increased their price target on Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. The Goldman Sachs Group boosted their price objective on Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, Citigroup upped their price objective on Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.00.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.